For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.
HealthDay on MSN2d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
GLP-1: Glucagon-like peptide-1; RA: receptor agonist ... and will be crucial to making a final assessment of where these medications fit into our algorithm for effectively managing Type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback